What it's for (Indications)
- Digoxin, commonly marketed as Lanoxin, is a cardiac glycoside primarily indicated for the treatment of mild to moderate heart failure with reduced ejection fraction (HFrEF) in adults, when symptoms persist despite optimal diuretic and angiotensin-converting enzyme (ACE) inhibitor therapy, or in patients intolerant to ACE inhibitors.
- Its use in heart failure aims to improve clinical symptoms, increase exercise tolerance, and reduce hospitalizations, though it has not been shown to reduce mortality in this setting.
- Additionally, digoxin is indicated for the control of ventricular rate in adult patients with chronic atrial fibrillation or atrial flutter, particularly in those with a coexisting diagnosis of heart failure or left ventricular dysfunction.
- It exerts its rate-controlling effects by slowing conduction through the atrioventricular (AV) node, thereby reducing the number of impulses reaching the ventricles.
- Its role in rate control is particularly valuable in patients where beta-blockers or calcium channel blockers are contraindicated or not tolerated, or as an adjunct to these therapies.
- It is crucial to note that digoxin is not indicated for the treatment of acute supraventricular arrhythmias without underlying heart failure or for the treatment of ventricular arrhythmias.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Digoxin dosage must be meticulously individualized based on the patient's clinical response, renal function, lean body weight, and serum digoxin concentrations, given its narrow therapeutic index. A typical digitalizing (loading) dose may be administered orally or intravenously to achieve therapeutic levels more rapidly, often divided over 12 to 24 hours, followed by a daily maintenance dose. For oral administration, loading doses can range from 0.5 to 1.5 mg total, given in divided doses. Maintenance doses typically range from 0.0625 mg to 0.5 mg daily, most commonly 0.125 mg to 0.25 mg daily, adjusted based on renal function, with lower doses required for patients with impaired kidney function or advanced age. Intravenous doses are usually 70-80% of oral doses. Regular monitoring of serum digoxin levels (ideally 6-8 hours post-dose to allow for distribution), electrolytes (potassium, magnesium, calcium), renal function, and cardiac rhythm is paramount to optimize efficacy and minimize the risk of toxicity. Therapeutic serum concentrations generally fall between 0.5 to 0.9 ng/mL for heart failure, though higher levels might be accepted for rate control in atrial fibrillation, provided there are no signs of toxicity. Dosing adjustments are frequently necessary, especially during initiation or if concomitant medications are added or discontinued. |
Safety & Warnings
Common Side Effects
- The adverse effects of digoxin are often dose-related and indicative of toxicity, owing to its narrow therapeutic window.
- Cardiovascular side effects are among the most serious and include various arrhythmias such as bradycardia, premature ventricular contractions, AV block (first, second, or third degree), ventricular tachycardia, and ventricular fibrillation, which can be life-threatening.
- Non-cardiac adverse effects frequently precede cardiac toxicity.
- Gastrointestinal disturbances are common and may include nausea, vomiting, anorexia, and diarrhea.
- Central nervous system effects can manifest as headache, fatigue, lethargy, malaise, confusion, disorientation, and even psychosis.
- Visual disturbances are characteristic of digoxin toxicity and can include blurred vision, halos around objects, yellow-green discoloration of vision (xanthopsia), and diplopia.
- Other less common side effects include gynecomastia, rash, and thrombocytopenia.
- Electrolyte imbalances, particularly hypokalemia, hypomagnesemia, and hypercalcemia, significantly exacerbate the risk of digoxin toxicity, making their monitoring and correction critical.
- Any new or worsening symptom in a patient on digoxin should prompt immediate evaluation for potential digoxin toxicity.
Serious Warnings
- Black Box Warning: Digoxin does not carry a formal FDA Black Box Warning. However, due to its narrow therapeutic index and significant potential for serious, life-threatening adverse events, particularly cardiac arrhythmias, a 'Serious Warnings' section is critically important. Patients receiving digoxin are at high risk of developing digoxin toxicity, which can manifest as various cardiac arrhythmias, including ventricular tachycardia or fibrillation, bradycardia, and high-degree AV block, any of which can be fatal. Non-cardiac symptoms such as nausea, vomiting, anorexia, and neurological disturbances (e.g., visual changes, confusion) often precede or accompany cardiac toxicity. The risk of toxicity is significantly increased by factors such as hypokalemia, hypomagnesemia, hypercalcemia, impaired renal function, hypothyroidism, and concurrent administration of numerous interacting medications. Close monitoring of serum digoxin levels, serum electrolytes (potassium, magnesium, calcium), and renal function is imperative throughout treatment. Patients and caregivers must be educated about the signs and symptoms of digoxin toxicity and instructed to seek immediate medical attention if they occur. In cases of suspected toxicity, digoxin administration should be withheld, and appropriate medical interventions, including correction of electrolyte imbalances and administration of digoxin-specific antibody fragments (Digoxin Immune Fab) in severe cases, should be initiated promptly.
- Digoxin possesses a narrow therapeutic index, necessitating careful monitoring and dose individualization to prevent toxicity, which can be severe or even fatal.
- Particular caution is advised in patients with impaired renal function, as digoxin is primarily renally cleared; dose reductions are mandatory, and more frequent monitoring of serum digoxin levels is essential.
- Elderly patients often have reduced renal clearance and are more susceptible to adverse effects, requiring lower doses and close surveillance.
- Electrolyte imbalances, especially hypokalemia, hypomagnesemia, and hypercalcemia, significantly predispose patients to digoxin toxicity by enhancing its effects on myocardial cells.
- Therefore, serum electrolyte levels must be regularly monitored and corrected.
- Patients with thyroid disorders, specifically hypothyroidism or hyperthyroidism, require careful dosing adjustments as thyroid status affects digoxin metabolism and sensitivity.
- Myocardial infarction, acute myocarditis, and severe respiratory disease can increase myocardial sensitivity to digoxin.
- Digoxin should be used with extreme caution in patients with Wolff-Parkinson-White syndrome and atrial fibrillation, as it may accelerate ventricular response leading to ventricular fibrillation.
- Numerous drug interactions can alter digoxin levels or enhance its effects, including amiodarone, verapamil, diltiazem, quinidine, macrolide antibiotics, and several diuretics, demanding vigilance and potential dose adjustments.
- Patients should be educated on the symptoms of digoxin toxicity and instructed to seek immediate medical attention if they experience any.
- The overall risk-benefit must be carefully assessed for each patient.
How it Works (Mechanism of Action)
Digoxin exerts its therapeutic effects primarily by inhibiting the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) pump in cardiac myocytes. This inhibition leads to an accumulation of intracellular sodium, which in turn reduces the activity of the sodium-calcium exchanger (NCX). The reduced extrusion of calcium by the NCX results in an increased intracellular calcium concentration within the cardiac muscle cells. This elevated intracellular calcium is then available to the contractile proteins (actin and myosin), leading to an enhanced force of myocardial contraction, a positive inotropic effect, which is beneficial in heart failure. Concurrently, digoxin exerts vagomimetic effects, enhancing vagal tone and signaling from the central nervous system to the heart. This action directly affects the atrioventricular (AV) node, slowing its conduction velocity and prolonging its refractory period. This negative dromotropic effect reduces the number of electrical impulses transmitted from the atria to the ventricles, thereby decreasing the ventricular rate in conditions like atrial fibrillation or atrial flutter. Digoxin also possesses mild peripheral vasoconstrictive properties at higher doses, but its primary hemodynamic benefits in heart failure are attributed to improved cardiac output and subsequent neurohormonal modulation. The interplay of these cellular and neurohumoral actions underlies its efficacy in improving cardiac function and controlling ventricular rate.